#TCRX hashtag - Bluesky

TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition TScan Therapeutics (NASDAQ: TCRX) reported updated ALLOHA™ Phase 1 data for TSC-101 in heme malignancy patients undergoing allogeneic HCT presented at ASH on Dec 6, 2025. As of a Sept 19, 2025 cut, treatment-arm outcomes showed improved relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) versus control.All 3 TSC-101 patients reaching two-year follow-up remained relapse-free versus 1 of 4 in control. No dose-limiting toxicities were observed. FDA agreed to a pivotal study design; pivotal start targeted Q2 2026. Manufacturing time reduced from 17 to 12 days.

3 months ago

#TCRX TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

www.stocktitan.net/news/TCRX/t-scan-therape...

0 0 0 0

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA ™ Phase 1 heme trial to be presented at the 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Made the strategic decision to prioritize clinical

4 months ago

#TCRX TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/TCRX/t-scan-therape...

0 0 0 0

Trade Alerts, Thursday September 11, 2025 – Crystal Equity Research

6 months ago

Small-cap stocks registering bearish MACD crossover signal, Thu Sept 11th - #ENTO #VSTM #TCRX #SRCE #RBBN #PINC #OSBC #MGNX #LOVE #ICCM #HSON #FISI $ELVA $DAWN $COGT $CCRN $BCAX $ACIC $TEN $SCM $PINE $ONL $NMM $MFA - More: crystalequityresearch.com/trade-alerts... - #smallcap

1 0 0 0

TScan's Novel Cancer Cell Therapy Reaches Critical Milestone as Q2 Revenue Surges 520% TScan prepares to treat first solid tumor patients with breakthrough TCR-T therapy. $218M cash runway extends to 2027. See trial updates and financial highlights.

7 months ago

#TCRX TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/TCRX/t-scan-therape...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

9 months ago

Small-cap stocks with improving money flow, Wed Jun 4th - #AEHR #CDNA #DSGN #INDI #LVLU #MCHX #NAAS #PLAY #SSSS #TCRX #XBIT #YEXT #XPOF #PL #NOAH #MLNK #KYN #GSL #DHT #CHPT #ADNT #WULF - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

10 months ago

Small-cap stocks with strong volume gains, Wed May 21st - #TCRX #CREX #EDBL #MRM #NUKK #SGMA #NIU #LTRY #LAES #IDN #GCL #CPSH #BDSX #AKYA #GOOS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

10 months ago

Small-cap stocks with strong volume declines, Tue May 20th - #SSII #TCRX #QMCO #OPTN #MTVA #CING #ASPI #CVU #RZB - More: crystalequityresearch.com/SmCpStr/ - #smallcap

1 0 0 0

TScan Therapeutics Reveals Solid Progress: Key Clinical Data Coming in 2025, $251M War Chest Secured TScan advances cancer therapies with upcoming trial data, plans new IND filing, and maintains strong $251M cash position. See milestone timeline and financial details.

10 months ago

#TCRX TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/TCRX/t-scan-therape...

0 0 0 0

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update TScan Therapeutics (NASDAQ: TCRX) reported its Q4 and full-year 2024 financial results, highlighting progress in its cancer treatment pipeline. The company's ALLOHA™ Phase 1 heme trial showed promising results with only 2 of 26 patients relapsing compared to 4 of 12 in the control arm.Key financial highlights include: Q4 2024 revenue of $0.7M (down from $7.2M in Q4 2023), full-year revenue of $2.8M (down from $21M in 2023), and a Q4 net loss of $35.8M. The company secured $30M through a registered direct offering at a 37% premium and refinanced its debt with a $52.5M term loan from SVB.R&D expenses increased to $107.4M for 2024 (from $88.2M in 2023) due to expanded clinical trials. With $290.1M in cash and equivalents, TScan expects to fund operations into Q1 2027. The company plans to initiate a registration trial for TSC-101 in H2 2025 and anticipates presenting multiplex TCR-T therapy data in the second half of 2025.

1 year ago

#TCRX TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/TCRX/t-scan-therape...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

1 year ago

Small-cap stocks with strong volume gains, Thu Feb 20th - #ANIX #VS #SABR #AMPL #CADL #FGEN #INSG #LUNG #NEGG #OESX #CYD #ENFN #HLF #MD #XYF #RCB #TIF #PRPH #TCRX #XOS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

TScan Therapeutics (TCRX) Secures $30M Premium-Priced Financing, Extends Cash Runway to 2027 TScan Therapeutics raises $30M through pre-funded warrants at 37% premium, strengthening its TCR-T cell therapy development pipeline with extended operational funding into Q1 2027.

1 year ago

#TCRX TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

www.stocktitan.net/news/TCRX/t-scan-therape...

0 0 0 0

TScan Therapeutics Secures Major $52.5M Financing Deal to Extend Cash Runway Through 2026 TScan secures strategic financing with SVB, including $32.5M first tranche to refinance debt and extend operations. Deal provides flexibility with optional $20M second tranche.

1 year ago

#TCRX TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

www.stocktitan.net/news/TCRX/t-scan-therape...

0 0 0 0